The Tumor Microenvironment Program at USC Norris was created in 2003. The concept behind this Program is that the fundamental investigation of the mechanisms that control the interaction between malignant cells and their nontransformed microenvironment should lead to the identification of novel targets for therapeutic intervention and better prognosticators. The overarching goal is to make innovative basic discoveries on the role of the tumor microenvironment (TME), and by interacting with other Programs of USC Norris, develop these discoveries into investigator-driven clinical trials. The Program has three scientific objectives: 1) to investigate the fundamental mechanisms of communication between cancer cells and their microenvironment; 2) to understand the contribution of viral-induced lymphangiogenesis/angiogenesis to Kaposi sarcoma; and 3) to understand the mechanisms of immune escape and develop new approaches to cancer immunotherapy. The Program Co-Leaders Yves DeClerck and Martin Kast have complementary recognized expertise in the tumor microenvironment and in immunotherapy, respectively. The Program brings together 28 members from 16 departments in four schools at USC with expertise and research interests in inflammation, tumor-stroma interaction, metastasis, angiogenesis, Kaposi sarcoma-associated Herpes Virus (KSHV), human papilloma virus (HPV)-mediated oncogenesis, and immunotherapy. The Program has obtained new funding in the tumor microenvironment (one U54, three R01s, one DoD) and in viral-mediated angiogenesis/lymphangiogenesis (one P01 and one R21). A unique aspect of this basic science program has been its commitment to translation. Over the last five years, the Program has been the hub where fundamental observations made by its members have led to nine clinical studies/trials. Research conducted by members of the Program has a unique impact on specific populations of the LA County catchment area, particularly children (neuroblastoma and childhood ALL), women of low economic status (HPV-induced cervical cancer), and HIV-infected patients (Kaposi sarcoma). During the current project period, Program members have published 319 papers, of which 40% are inter-programmatic, 17% are intra-programmatic, and 28% inter-institutional. Program members have $11M (direct costs) in peer-review funding, with 40% from NCI and 27% from other NIH sources, and 5% from other peer-reviewed sources.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee H - Clinical Groups (NCI)
Program Officer
He, Min
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Southern California
Los Angeles
United States
Zip Code
Valentin-Torres, Alice; Savarin, Carine; Barnett, Joslyn et al. (2018) Blockade of sustained tumor necrosis factor in a transgenic model of progressive autoimmune encephalomyelitis limits oligodendrocyte apoptosis and promotes oligodendrocyte maturation. J Neuroinflammation 15:121
Ricker, Charité N; Koff, Rachel B; Qu, Chenxu et al. (2018) Patient communication of cancer genetic test results in a diverse population. Transl Behav Med 8:85-94
Jayne, Jordanna G; Bensman, Timothy J; Schaal, Justin B et al. (2018) Rhesus ?-Defensin-1 Attenuates Endotoxin-induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment. Am J Respir Cell Mol Biol 58:310-319
Tobin, Jessica; Miller, Kimberly A; Baezconde-Garbanati, Lourdes et al. (2018) Acculturation, Mental Health, and Quality of Life among Hispanic Childhood Cancer Survivors: A Latent Class Analysis. Ethn Dis 28:55-60
Harris, Holly R; Babic, Ana; Webb, Penelope M et al. (2018) Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 27:174-182
Lee, Brian H; Stallcup, Michael R (2018) Different chromatin and DNA sequence characteristics define glucocorticoid receptor binding sites that are blocked or not blocked by coregulator Hic-5. PLoS One 13:e0196965
Matsusaka, S; Wu, A H; Cao, S et al. (2018) Prognostic impact of FOXF1 polymorphisms in gastric cancer patients. Pharmacogenomics J 18:262-269
Woodham, Andrew W; Cheloha, Ross W; Ling, Jingjing et al. (2018) Nanobody-Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses. Cancer Immunol Res 6:870-880
Veyseh, Maedah; Ricker, Charite; Espenschied, Carin et al. (2018) Secondary Germline Finding in Liquid Biopsy of a Deceased Patient; Case Report and Review of the Literature. Front Oncol 8:259
Vannini, Ivan; Fanini, Francesca; Fabbri, Muller (2018) Emerging roles of microRNAs in cancer. Curr Opin Genet Dev 48:128-133

Showing the most recent 10 out of 842 publications